| Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment E Raschi, M Fusaroli, A Ardizzoni, E Poluzzi, F De Ponti Breast Cancer Research and Treatment 186, 219-227, 2021 | 70 | 2021 |
| Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID‐19 M Gatti, M Fusaroli, P Caraceni, E Poluzzi, F De Ponti, E Raschi British journal of clinical pharmacology 87 (3), 1533-1540, 2021 | 50 | 2021 |
| Post-marketing surveillance of CAR-T-cell therapies: Analysis of the FDA adverse event reporting system (FAERS) database M Fusaroli, V Isgrò, PM Cutroneo, C Ferrajolo, V Cirillo, F Del Bufalo, ... Drug Safety 45 (8), 891-908, 2022 | 28 | 2022 |
| Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system E Raschi, M Fusaroli, M La Placa, A Ardizzoni, C Zamagni, E Poluzzi, ... American Journal of Clinical Dermatology, 1-9, 2022 | 26 | 2022 |
| Thromboembolic events with cyclin-dependent kinase 4/6 inhibitors in the FDA adverse event reporting system E Raschi, M Fusaroli, A Ardizzoni, E Poluzzi, F De Ponti Cancers 13 (8), 1758, 2021 | 25 | 2021 |
| Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions M Iommi, S Rosa, M Fusaroli, P Rucci, MP Fantini, E Poluzzi PLoS One 15 (10), e0240899, 2020 | 20 | 2020 |
| Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system M Fusaroli, E Raschi, V Giunchi, M Menchetti, R Rimondini Giorgini, ... International Journal of Neuropsychopharmacology 25 (9), 727-736, 2022 | 17 | 2022 |
| Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse event … M Sisi, M Fusaroli, A De Giglio, F Facchinetti, A Ardizzoni, E Raschi, ... Targeted Oncology 17 (1), 43-51, 2022 | 16 | 2022 |
| Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis DM Filippini, M Gatti, V Di Martino, S Cavalieri, M Fusaroli, A Ardizzoni, ... International Journal of Cancer 149 (3), 675-683, 2021 | 14 | 2021 |
| Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system M Gatti, M Fusaroli, E Raschi, U Moretti, E Poluzzi, F De Ponti Expert Opinion on Drug Safety 20 (11), 1421-1431, 2021 | 11 | 2021 |
| The changing face of drug-induced adrenal insufficiency in the Food and Drug Administration adverse event reporting system E Raschi, M Fusaroli, F Massari, V Mollica, A Repaci, A Ardizzoni, ... The Journal of Clinical Endocrinology & Metabolism 107 (8), e3107-e3114, 2022 | 10 | 2022 |
| Development of a network-based signal detection tool: the COVID-19 adversome in the FDA adverse event reporting system M Fusaroli, E Raschi, M Gatti, F De Ponti, E Poluzzi Frontiers in Pharmacology 12, 740707, 2021 | 10 | 2021 |
| Direct oral anticoagulants and interstitial lung disease: emerging clues from pharmacovigilance E Raschi, M Fusaroli, I Diemberger, E Poluzzi Drug Safety 43, 1191-1194, 2020 | 10 | 2020 |
| adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor: analysis of the FDA adverse event reporting system E Raschi, M Fusaroli, V Giunchi, A Repaci, C Pelusi, V Mollica, F Massari, ... Cancers 14 (19), 4610, 2022 | 9 | 2022 |
| Strategies and tools for supporting the appropriateness of drug use in older people C Lunghi, C Trevisan, M Fusaroli, V Giunchi, E Raschi, E Sangiorgi, ... Pharmaceuticals 15 (8), 977, 2022 | 9 | 2022 |
| Amyotrophic lateral sclerosis as an adverse drug reaction: a disproportionality analysis of the food and drug administration adverse event reporting system A Gaimari, M Fusaroli, E Raschi, E Baldin, L Vignatelli, F Nonino, ... Drug Safety 45 (6), 663-673, 2022 | 9 | 2022 |
| Interpretation of pharmacovigilance disproportionality analyses C Khouri, M Fusaroli, F Salvo, E Raschi Clinical Pharmacology and Therapeutics, 2023 | 8 | 2023 |
| Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study M Fusaroli, V Giunchi, V Battini, M Gringeri, R Rimondini, M Menchetti, ... Psychiatry and Clinical Neurosciences 77 (3), 160-167, 2023 | 8 | 2023 |
| Deliberate self-poisoning: real-time characterization of suicidal habits and toxidromes in the food and drug administration adverse event reporting system M Fusaroli, G Pelletti, V Giunchi, C Pugliese, M Bartolucci, EN Necibi, ... Drug safety 46 (3), 283-295, 2023 | 7 | 2023 |
| Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System R Noseda, L Müller, F Bedussi, M Fusaroli, E Raschi, A Ceschi Cancers 15 (1), 173, 2022 | 7 | 2022 |
Fabrizio De PontiProfessor of Pharmacology, University of Bologna在 unibo.it 的电子邮件经过验证
